We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Bacterial Growth Assay Predicts COVID-19 Severity From Plasma

By LabMedica International staff writers
Posted on 14 Jul 2026

COVID-19 presents with a wide clinical spectrum, from mild illness to severe, life-threatening disease. More...

Early differentiation between patients likely to remain mild and those at risk of severe progression is vital for care pathways. Biological samples contain multiplexed chemical signals that may encode this prognostic information. New findings demonstrate that growth responses of Escherichia coli to patient plasma can distinguish mild from severe COVID-19.

INRAE, in collaboration with Grenoble Alpes University Hospital, Université Grenoble Alpes, and the CEA, describes an approach that uses Escherichia coli (E. coli) as a living bacterial reservoir computer. Without genetic modification, the bacterium is placed in direct contact with plasma from patients with COVID-19. It adapts its metabolism and growth to the plasma’s chemical composition, generating a growth curve that reflects the detected signals.

The resulting growth curve is measured and treated as an information-processing output. In clinical samples, this readout was used to classify whether a patient was likely to develop mild or severe COVID-19. For additional computational tasks, researchers translated problems into defined nutrient mixtures that elicited analogous growth-based responses. Notably, the bacterium performed tasks typically assigned to machine-learning algorithms without prior training.

The research was published in Cell Systems and coordinated by INRAE, with participation from Grenoble Alpes University Hospital, Université Grenoble Alpes, and the CEA. The authors indicate that genetically unmodified living organisms can convert the complexity of a sample into usable information. This approach could lead to simple, affordable diagnostic and prognostic tools that can be deployed in settings with limited technical resources. 

The team plans to explore additional applications, including monitoring environmental samples such as urban wastewater and analyzing other types of clinical specimens. More broadly, the work highlights the potential of living systems as platforms for information processing and sensing.

Related Links
INRAE 
Grenoble Alpes University Hospital


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Platelet Function Analyzer
PL-12
Manual Pipetting Aid
Pipette Controllers macro
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The method combines ultrasonic and fluorescence techniques to track amyloid aggregation in real time (Image Credit: Shutterstock)

Blood Test Measures Amyloid Seeding Activity to Detect Alzheimer’s Disease

Early, accurate diagnosis of Alzheimer’s disease (AD) remains challenging in routine practice, despite its role as the leading cause of dementia worldwide. Confirmation typically relies on cerebrospinal... Read more

Pathology

view channel
Image: TRUECAM automatically eliminates ambiguous or uninformative regions in whole-slide pathology images, enhancing the reliability of diagnostic analysis. (Photo courtesy of PolyU)

AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis

Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more

Industry

view channel
Image: HealthTab will distribute the Abbott Afinion 2 Analyzer to NHS-linked pharmacies for hemoglobin A1c (HbA1c) and lipid profile testing. (Photo courtesy of Abbott)

New Collaboration Expands Point-of-Care Testing Across UK Community Pharmacies

HealthTab, a wholly owned subsidiary of Avricore Health, has entered a formal collaboration agreement with Abbott to supply and distribute Abbott’s point-of-care testing products in the UK through the... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.